Neutropenia News and Research

RSS

Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils, the most important type of white blood cell, in the blood.

Sunesis Pharmaceuticals presents data of Voreloxin in patients with acute myeloid leukemia and ovarian cancer

Sunesis Pharmaceuticals, Inc. presented data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8.

7 Nov 2008

Sunesis Pharmaceuticals updates clinical data on Voreloxin in platinum-resistant ovarian cancer

Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.

27 Oct 2008

ZymoGenetics presents interim Interleukin 21 phase 2 results in renal cell cancer

ZymoGenetics, Inc. presented interim results today from a Phase 2 clinical trial evaluating Interleukin 21 (IL-21) in combination with Nexavar (sorafenib) tablets in patients with metastatic renal cell cancer.

22 Oct 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

FDA lifts clinical hold on Genta's Tesetaxel

Genta Incorporated announced that the Company has received notification from the U.S. Food and Drug Administration (FDA) that Genta may resume clinical trials with tesetaxel, a leading oral taxane in Genta's oncology product portfolio.

23 Jun 2008

Telik announces patents on TELINTRA compounds

Telik, Inc. announced today that the European Patent Office has issued notices of allowance for two applications covering new compounds related to one of Telik's lead clinical candidates, TELINTRA.

11 Jun 2008

Role of breastfeeding in preventing infant death, HIV infection in developing countries

In many poor countries, mothers with HIV face a stark choice: to nurse their infants, and risk passing on HIV through their breast milk - or to formula feed, and deprive their infants of much of the natural immunity needed to protect against fatal diseases of early infancy. Now, two studies supported by the National Institutes of Health offer insights into preventing early death and HIV infection among breastfeeding infants of mothers with HIV in these countries.

5 Jun 2008

Paclitaxel Poliglumex/Capecitabine regimen well tolerated and active in metastatic breast cancer

At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (Opaxio, CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC).

3 Jun 2008

Spectrum Pharmaceuticals to present data on Ortataxel in breast cancer at major oncology meeting

Spectrum Pharmaceuticals, Inc., will present Phase 2 data on ortataxel at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 to June 3, 2008 at the McCormick Place Convention Center in Chicago, Illinois.

19 May 2008

Biosimilar protein cooperation

A biosimilar protein that can be used to treat neutropenia (a side effect of cancer chemotherapy) is to be developed by Apotex Inc. of Canada in collaboration with Intas Biopharmaceuticals Limited (IBPL).

6 May 2008

Genentech updates on phase III study of Avastin plus chemo in first-line, advanced, non-squamous, non-small cell lung cancer

Genentech, Inc. has announced an update for the previously reported Roche-sponsored international Phase III clinical study (AVAiL) of Avastin (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC).

21 Apr 2008

Treatment with sunitinib slows tumor growth and spread of liver cancer

Treatment with sunitinib slows tumor growth and reduces the risk of metastasis in patients with hepatocellular carcinoma, an aggressive cancer of the liver, researchers report.

15 Apr 2008

Chemotherapy with chemoradiation for pancreatic cancer has small survival benefit

The addition of the drug gemcitabine with chemoradiation for the treatment of patients who had surgery for pancreatic cancer was associated with a survival benefit, although this improvement was not statistically significant, according to a study in the March 5 issue of JAMA.

6 Mar 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008

Quality of care for inflammatory bowel disease patients can be improved

Inflammatory bowel disease (IBD) is a chronic recurrent gastrointestinal disease.

26 Feb 2008

Risk factors for severe RSV infection in immunocompromised children

St. Jude Children's Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help clinicians improve guidelines for managing these infected children.

4 Feb 2008

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca has announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.

3 Jan 2008

Study results from Zolinza (vorinostat) in combination with bortezomib for multiple myeloma trial

Results from two investigational Phase I trials of ZOLINZA (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma.

10 Dec 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007